Skip to content

Author

Shu-Qun Zhang

We have 2 of 30 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Oct 2026

Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.

BACKGROUND Patients with heavily pretreated hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer have few treatment options. Izalontamab brengitecan (iza-bren) is a first-in-class, epidermal growth factor receptor and HER3 bispecific antibody-drug conjugate that cont...

B. Lan, Ye-Hui Shi, Xi-Ying Shao et al. · 0 citations
Sep 2026

ZUP1 as a Novel Potential Oncogenic Driver and Prognostic Biomarker in Breast Cancer.

This study identifies ZUP1 as a potential oncogenic factor and a robust independent prognostic biomarker in breast cancer and suggests that ZUP1 is a novel multifaceted biomarker with significant implications for personalized treatment strategies in breast cancer.

Weimiao Li, Changyou Shan, Shu-Qun Zhang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.